Squarepoint
MRTX

Squarepoint’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Squarepoint’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,600
Closed -$789K – 3546
2022
Q1 		$789K Buy
+9,600
New +$982K ﹤0.01% 1728

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Squarepoint's MRTX Position: Q2 2023 in Review

Squarepoint sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 28,189 shares — an estimated $1.05M sold.

Squarepoint first reported a position in MRTX in Q3 2017 and held it in 13 quarters. The position peaked at $6.08M in Q1 2019. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Squarepoint reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Squarepoint sold 28,189 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.05M.
  • Squarepoint first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Squarepoint's Mirati Therapeutics, Inc. Common Stock position peaked at $6.08M in Q1 2019.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.